Form 4: Sarepta Therapeutics Director Kathryn Boor Reports Stock Transactions

Director Kathryn Boor reports acquisition and disposal of Sarepta Therapeutics common stock and stock options.

Summary

• Kathryn Jean Boor, a director of Sarepta Therapeutics, reported changes in her beneficial ownership of the company's securities.
• On March 10, 2025, Ms. Boor acquired 2,383 shares of common stock through restricted stock units (RSUs).
• Ms. Boor also disposed of 8,263 shares of common stock.
• Additionally, Ms. Boor acquired stock options for 4,792 shares of common stock at an exercise price of $99.69, exercisable from March 10, 2026, to March 10, 2035.
• Following these transactions, Ms. Boor directly owns 4,792 derivative securities and 8,263 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing primarily reports transactions without providing explicit positive or negative signals. The disposal of shares is balanced by the acquisition of RSUs and stock options.

Positives

• The acquisition of restricted stock units and stock options could indicate confidence in the company's future performance.

Negatives

• The disposal of 8,263 shares could be interpreted negatively, although the reason for disposal is not specified.

Risks

• The value of the stock options is dependent on the future stock price of Sarepta Therapeutics.
• The vesting of the RSUs is contingent upon continued service or other conditions.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock. These filings are closely watched by investors for signals about management's view of the company's prospects.

Comparison to Industry Standards

• Comparing the option exercise price and vesting schedule to those of similar biotech companies like BioMarin or Vertex Pharmaceuticals would provide context.
• Analyzing the ratio of stock options to total shares outstanding relative to industry peers can offer insights into the company's compensation practices.

Stakeholder Impact

• Shareholders may interpret the transactions as a signal of the director's confidence or lack thereof in the company's future performance.
• Employees holding company stock or options may be interested in the director's transactions.

Key Dates